The Centers for Disease Control and Prevention (CDC) announced that genetic analysis of samples from a Louisiana resident, the first severe case of H5N1 bird flu in the United States, revealed rare mutations. The patient, aged over 65, was hospitalized with severe respiratory illness after likely exposure to infected birds in a backyard flock.
Read More: Former US president Bill Clinton hospitalized with fever
The CDC reported that mutations were found in the virus’ hemagglutinin (HA) gene, which is critical for the virus to attach to human host cells. Notably, these mutations were absent in samples from the infected birds, suggesting they developed during the patient’s illness rather than at the point of transmission.
Similarities With Canadian Case
One of the mutations identified in the Louisiana case was also observed in a teenager from British Columbia, Canada, who contracted H5N1 earlier this year and experienced a severe infection. These mutations could potentially enhance the virus’ ability to bind to cell receptors in the human upper respiratory tract—a factor linked to higher transmissibility.
Dr. Angela Rasmussen, a virologist at the Vaccine and Infectious Disease Organization in Canada, acknowledged the gravity of these findings. “More [genetic] sequences from humans is a trend we need to reverse,” she cautioned, highlighting the risks of increasing human infections.
Mutations Likely Patient-Driven
The CDC emphasized that the mutations likely arose during the clinical course of the Louisiana patient’s advanced disease rather than being widespread in the circulating virus. This distinction is critical because mutations in the environment would pose a greater threat of the virus becoming more transmissible.
Scott Hensley, a microbiology professor at the University of Pennsylvania, underscored that while the mutations raise concerns, they have not yet been linked to human-to-human transmission. “Attachment is a prerequisite [for transmissibility], but it might not be enough,” he explained.
Broader Context of H5N1 in the U.S.
The Louisiana patient was infected with the D1.1 genotype of the H5N1 virus, which is primarily found in wild birds and poultry. A separate genotype, B3.13, has been associated with outbreaks in dairy cows and has not caused severe human cases in the United States.
The U.S. has confirmed 65 cases of H5N1 in humans in 2024, with the majority linked to dairy herds and poultry farms. Despite the high number of cases, severe illnesses remain rare, with the Louisiana and British Columbia cases being the only two severe infections reported in North America this year.
Public Health Implications
The CDC and health experts agree that the overall risk to the general public remains low. There has been no evidence of onward transmission from either the Louisiana patient or the Canadian teenager. However, the detection of mutations underscores the importance of vigilant genomic surveillance in humans and animals.
The CDC noted that the mutations have not affected the efficacy of existing antiviral drugs or vaccines. Moreover, the sequences from the Louisiana case are closely related to strains that could be used to manufacture vaccines if needed.
Calls for Caution
Experts have cautioned against overinterpreting these findings. Dr. Paul Offit, a vaccine scientist, emphasized that more evidence is needed to confirm whether these mutations truly increase the virus’ ability to infect humans. “We don’t know yet that it binds well,” he stated, urging patience while further research is conducted.
Global Perspective and Future Steps
Globally, virologists are concerned about the rising number of human cases of H5N1. Rasmussen and other experts warn that every human infection provides an opportunity for the virus to evolve into a pandemic strain.
Read More: US withdraws $10 million bounty for new Syrian leader
To mitigate this risk, the CDC continues to collaborate with state health departments, including Louisiana’s, to monitor outbreaks and conduct genomic studies. The agency is also investigating samples taken later in the Louisiana patient’s infection to determine if additional mutations occurred.